Protein Turnover in Preterm Infants - Feeding of Target Fortified Breast Milk With Different Macronutrient Composition to Improve Growth

February 27, 2023 updated by: Niels Rochow, MD, PhD, Paracelsus Medical University

Protein Turnover in Preterm Infants - Feeding of Target Fortified Breast Milk With Different Carbohydrate and Fat Composition to Improve Growth

The purpose of this study is to measure protein turnover rates in preterm infants.

Study Overview

Detailed Description

After being informed about the study and potential risks, all parents giving written informed consent the principal investigator will determine the eligibility for study entry. Patients who met the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to fortified breast milk with higher fat composition to fortified breast milk with higher carbohydrate composition. Both groups will receive a stable protein composition. The participants will receive the intervention for 3 consecutive weeks.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Nürnberg, Germany, 90471
      • Rostock, Germany, 18057
      • Rostock, Germany, 18059
        • Not yet recruiting
        • Klinikum Südstadt Rostock Abteilung für Neonatologie und Neonatologische Intensivmedizin
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 months to 7 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Gestational age < 32 weeks
  • Enteral nutrition >150 mL / kg / d

Exclusion Criteria:

  • gastrointestinal malformations
  • Enterostoma
  • short bowel syndrome
  • necrotizing enterocolitis
  • kidney disease
  • Foreseeable transfer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Macronutrient_CARB
High carbs, low fat composition.
Breast milk 150 to 170 mL/d; Target fortification: 9.0 g/100mL COH, 3.0 g/100mL protein, 4.0 g/100mL fat, 86.4 kcal/100mL
Active Comparator: Macronutrient_FAT
Low carbs, high fat composition.
Breast milk 150 to 170 mL/d; Target fortification: 5.5 g/100mL COH, 3.0 g/100mL protein, 5.5 g/100mL fat, 86 kcal/100mL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
weight gain
Time Frame: daily for 3 weeks
weight gain in gram
daily for 3 weeks
Protein turnover and net protein gain
Time Frame: weekly for 3 weeks
Tracer N15 labelled amino acids
weekly for 3 weeks
Protein excretion
Time Frame: weekly for 3 weeks
Urinary urea in mg/dL and urine volume in mL will be combined to report protein excretion per urine sample (g/kg/d).
weekly for 3 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Nutritional intake
Time Frame: daily for 3 weeks
Volume of Breast Milk in mL/kg/d, Lactose in g/100mL, protein g/100mL, fat g/100mL will be combinded to report energy in kcal/kg/d
daily for 3 weeks
head circumference
Time Frame: daily for 3 weeks
in cm
daily for 3 weeks
body length
Time Frame: daily for 3 weeks
in cm
daily for 3 weeks
body composition
Time Frame: weekly for 3 weeks
Fat mass in g, fat-free mass g, volume in L will be combined to report body density in kg/L
weekly for 3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 21, 2021

Primary Completion (Anticipated)

August 31, 2024

Study Completion (Anticipated)

August 31, 2024

Study Registration Dates

First Submitted

April 12, 2021

First Submitted That Met QC Criteria

April 16, 2021

First Posted (Actual)

April 22, 2021

Study Record Updates

Last Update Posted (Estimate)

February 28, 2023

Last Update Submitted That Met QC Criteria

February 27, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • SZ_D_069_20-IX-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Infant Development

Subscribe